Rangering i aksjer
#26169
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Handel Molecure S.A. (MOC)
Pris MOC pris med markedsverdi på B
Markedsverdi av Molecure S.A.(MOC)
Markedsverdi: $42.88M
Per August 2026 har Molecure S.A. en markedsverdi på $42.88M. Dette gjør Molecure S.A. til det 26169th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Molecure S.A. fra 2018 til 2026
MOC sammenlignet med topp 5 mest populære stocks
| Pris på MOC |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.242T
|
+12,225,855.89%
|
|
|
|
|
$4.650T
|
+10,846,038.05%
|
|
|
|
|
$4.111T
|
+9,588,261.83%
|
|
|
|
|
$3.578T
|
+8,344,314.81%
|
|
|
|
|
$2.812T
|
+6,558,242.86%
|
